AEROLONE
Clinical safety rating
cautionComprehensive clinical and safety monograph for AEROLONE (AEROLONE).
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
| Metabolism | Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding. |
| Bioavailability | Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; Inhalation: 5-15 minutes; Intravenous: 2-5 minutes. |
| Duration of Action | Oral: 8-12 hours; Inhalation: 4-6 hours; Intravenous: 4-8 hours. Duration is dose-dependent and may be shorter with single doses. |
| Molecular Weight | 476.6 |
AEROLONE is not a recognized drug; no standard dosing available.
| Dosage form | SOLUTION |
| Renal impairment | No data; not applicable. |
| Liver impairment | No data; not applicable. |
| Pediatric use | No data; not applicable. |
| Geriatric use | No data; not applicable. |
| 1st trimester | Limited data; risk cannot be ruled out. Avoid unless clearly necessary. |
| 2nd trimester | Limited data; may be used if benefit outweighs risk. |
| 3rd trimester | May cause premature labor or fetal tachycardia; use with caution. |
Clinical note
Comprehensive clinical and safety monograph for AEROLONE (AEROLONE).
| Placental transfer | Crosses placenta; extent unknown. |
| Breastfeeding | Excreted in breast milk in low amounts; consider risk to infant, especially in premature or high-dose use. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure. |
| Fetal Monitoring | Monitor maternal forced expiratory volume in 1 second (FEV1) and symptom control. No specific fetal monitoring required beyond standard prenatal care. In cases of prolonged high-dose use, consider neonatal monitoring for adrenal suppression (e.g., transient adrenal insufficiency signs like lethargy, feeding difficulty). |
| Fertility Effects | No known impairment of male or female fertility based on limited animal studies (no effect on fertility in rats at doses up to 50 mcg/kg/day). In humans, no data suggest adverse effects on fertility from inhaled fluticasone. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to AEROLONE or any componentStatus asthmaticus without adequate supportive therapy
| Precautions | Paradoxical bronchospasm, Cardiovascular effects (e.g., increased heart rate, QT prolongation), Hypokalemia, Hyperglycemia |
| Food/Dietary | No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component. |
| Clinical Pearls | AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing. |
| Patient Advice | Use AEROLONE exactly as prescribed; do not exceed recommended dose. · Rinse your mouth with water after each use (do not swallow) to prevent thrush. · This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you. · Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing. · Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction. |
Loading safety data…